Granisetron Transdermal System Articles
ProStrakan faces Abstral production shortage and FDA hold-up of Sancuso, as CEO resigns
8 September 2010
Painful wait for ProStrakan on Abstral’s US approval
18 August 2010
ProStrakan’s Sancuso out-licensed by Solasia in Asia
4 March 2010
ProStrakan's 2008 revenue up 23%
30 March 2009
Stock Commentary - Europe - week to Feb 16, 2009
23 February 2009
ProStrakan signs two Sancuso marketing deals
16 February 2009
ProStrakan's Sancuso launched in USA
10 November 2008
ProStrakan partners with NewBridge for Sancuso
10 November 2008
Prostrakan a "buy" on early UK Abstral appro
29 September 2008
JapanBridge to market Sancuso in SE Asia
2 June 2008
FDA delays release of ProStrakan's Sancuso
28 April 2008
ProStrakan's 2007 sales exceed expectations
21 January 2008
NovaQuest signs accord on ProStrakan's Sancuso
29 October 2007
ProStrakan's 1st-half revenues jump 28%
24 September 2007
ProStrakan out-licenses Sancuso in S Korea
20 August 2007
ProStrakan submits Sancuso MAA
23 July 2007
ProStrakan narrows 2006 loss to L18.3M
9 April 2007
Stock Commentary - Europe - week to Dec 11, 2006
18 December 2006
ProStrakan half-year sales up 28% to L16.1M
25 September 2006
ProStraken provides update on Sancuso and Tostrex trials
13 February 2006
Showing 1-22 of 22 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
